Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAIC gemcitabine + cisplatin + fluorouracil with lenvatinib and sintilimab for unresectable intrahepatic cholangiocarcinoma
ChiCTR2400094538Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Dec 2024
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine, cisplatin, fluorouracil, lenvatinib and sintilimab in intrahepatic cholangiocarcinoma (ICC), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Progression-free survival. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
gemcitabinecisplatinfluorouracillenvatinibsintilimab
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on ChiCTR2400094538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400094538.